Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
DGPharma from Gent, company number BE0508925544, closed financial year 2024 with a result of € 65,307 after tax. For that financial year DGPharma recorded a gross margin of € 94,120 and equity of € 571,787. Compared with financial year 2023, the result moved from € 59,780 to € 65,307. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2025.
€ 571,787
▲ 13% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 65,307
▲ 9% vs 2023
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 271,787.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 700,871
▼ 20% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 71,734
▲ 105% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 152,779 | € 107,194 | € 155,522 | € 94,120 | ▼ 39% |
| Profit after taxes | € 114,141 | € 66,395 | € 59,780 | € 65,307 | ▲ 9% |
| Equity | € 380,305 | € 446,700 | € 506,480 | € 571,787 | ▲ 13% |
| Total debts | € 324,317 | € 560,883 | € 906,659 | € 772,606 | ▼ 15% |
| Cash | € 185,062 | € 118,242 | € 0 | - | |
| Retained profit | € 80,305 | € 146,700 | € 206,480 | € 271,787 | ▲ 32% |
| Dividend | € 100,000 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 704,622 | € 1,007,584 | € 1,413,139 | € 1,344,393 | ▼ 5% |
Key figures of DGPharma, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to DGPharma?
What happened at DGPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 65,307 (▲ 9% vs 2023). Source: NBB ↗
- AQUITANIA BV became a director. NBB
- CREDOPHAR BV became a director. NBB
- FARMAFENDER BV became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 114,141 profit in 2021 to € 65,307 profit in 2024.
Paid € 98,255 in corporate taxes since 2021.
Best year ever: 2021, with € 114,141 profit.
Paid out € 100,000 in dividends to the owners in total.
A new publication or filing at DGPharma? We notify you, reason included.
Follow DGPharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Labophar comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
DGPharmaBehind DGPharma are AQUITANIA BV, CREDOPHAR BV and FARMAFENDER BV. The shares are held by Labophar (100%).
Directors
According to the 2024 annual accounts
Director · represented by IMSCHOOT ANJA
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium, Labophar, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL, CREDOPHAR +1 more
since 2022
Director · represented by DEBEL MARIO
Owns 100% via Labophar
Also active at: b+pharma Belgium, Labophar
since 2022
Director · represented by VAN PETEGHEM BRAM
Also active at: b+pharma Belgium, Labophar
since 2022
Shareholders
Labophar · holding of CREDOPHAR BV
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
Ceres Pharma
€ 35.3 million revenue · 2025
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0508.925.544
- VAT number
- BE 0508.925.544
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- DGPharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 2012
- Peppol
- Active · Active since 1 Aug 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Overige detailhandel in voedingsmiddelen, neg
Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Groothandel in andere voedingsmiddelen, neg
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering